Skip to main content

Rituximab in cutaneous B-cell lymphoma: a report of two cases

Buy Article:

$51.00 plus tax (Refund Policy)


We report two patients with primary cutaneous B-cell lymphoma who were treated with rituximab, a new anti-CD20 monoclonal antibody. The first patient, who had a diffuse large B-cell lymphoma of the lower leg, achieved an 85% improvement. The second patient, who had a primary cutaneous B-cell lymphoma, which had undergone high-grade transformation and systemic spread, achieved a minor response of approximately 30%. Both patients subsequently relapsed. The first patient achieved complete clearance with a second course of rituximab given with systemic chemotherapy, but again relapsed. Treatment with rituximab has been reported to produce response rates of 48% in relapsed systemic low-grade or follicular lymphoma, but there are no previous reports of the use of rituximab in primary cutaneous B-cell lymphoma.

Keywords: anti-CD20 monoclonal antibody therapy; cutaneous B-cell lymphoma; rituximab

Document Type: Research Article


Affiliations: Skin Tumour Unit, St John’s Institute of Dermatology, St Thomas’ Hospital (GKT), London SE1 7EH, U.K.

Publication date: 2000-07-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more